Imunon’s shares soar after IL-12 therapy success in Phase II trial
In the intent-to-treat cohort, IMNN-001 plus chemotherapy offered a median 11.1-month increase in overall survival versus chemotherapy alone.
In the intent-to-treat cohort, IMNN-001 plus chemotherapy offered a median 11.1-month increase in overall survival versus chemotherapy alone.
What's Your Reaction?
